BRAF V600E Positive Papillary Thyroid Carcinoma (TERT and TP53 Mutation Coexistence Excluded): Correlation of Clinicopathological Features and the Extent of Surgical Treatment and Its Complications

Overview

Journal J Appl Biomed

Specialties Biomedical Engineering
General Medicine

Date 2025 Mar 4

PMID 40033809

Authors

Jiri Hlozek

Jan Rotnagl

Richard Holy

Tereza Hlozkova

Barbora Pekova Bulanova

Vlasta Kuklikova

Bela Bendlova

Jiri Soukup

Petr Hrabal

Jaromir Astl

Affiliations

Soon will be listed here.

Abstract

Introduction: Papillary thyroid carcinoma (PTC) frequently harbors the BRAF V600E mutation. Recent research suggests that aggressive behavior in BRAF V600E+ PTC may be due to an undetected mutation in the TERT gene. This study aims to observe the clinicopathological features of BRAF V600+ PTC and correlate them with surgical treatment complications.

Methods: A retrospective analysis was conducted on the BRAF V600E+ PTC cohort from July 2019 to January 2023. The histopathological features and surgical treatment (total thyroidectomy - group A, total thyroidectomy + central block neck dissection - group B) complications were correlated. Patients with TERT and TP53 mutation were excluded. Next-generation sequencing and real-time PCR were used for genetic analysis.

Results: Out of 121 PTCs, 65 cases showed BRAF V600E mutation with the following features: intracapsular spread (13.8%), extracapsular spread (27.7%), extrathyroidal spread (15.4%), multifocality (26.2%), angioinvasion (12.3%), and local metastasis (27.7%). The incidence of surgical complications in group A/B was: reversible recurrent laryngeal nerve (RLN) paresis 3.7/7.1%, RLN paresis permanent 0/2.4%, paresthesia 6.8/23.8%, hypocalcemia 36.4/61.9% on day 1 and 27.3/33.3% on day 3, and bleeding 2.3/9.5%. There was no significant difference in clinicopathological features between the BRAF V600E+ and BRAF V600E- PTC groups. Group B had a significantly higher incidence of hypoacalcaemia on postoperative day 1 (p = 0.047).

Conclusion: The BRAF V600E mutation will certainly remain important in the preoperative diagnosis of PTC. The more radical surgical procedures currently recommended may be abandoned in the future, particularly elective CLND, which has a higher risk of postoperative complications.

References

Ali S, Baloch Z, Cochand-Priollet B, Schmitt F, Vielh P, VanderLaan P . The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2023; 33(9):1039-1044. DOI: 10.1089/thy.2023.0141. View

Bulanova Pekova B, Sykorova V, Mastnikova K, Vaclavikova E, Moravcova J, Vlcek P . RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis. Endocr Relat Cancer. 2023; 30(12). PMC: 10620462. DOI: 10.1530/ERC-23-0117. View

Calo P, Conzo G, Raffaelli M, Medas F, Gambardella C, De Crea C . Total thyroidectomy alone versus ipsilateral versus bilateral prophylactic central neck dissection in clinically node-negative differentiated thyroid carcinoma. A retrospective multicenter study. Eur J Surg Oncol. 2016; 43(1):126-132. DOI: 10.1016/j.ejso.2016.09.017. View

Carty S, Ohori N, Hilko D, McCoy K, French E, Manroa P . The Clinical Utility of Molecular Testing in the Management of Thyroid Follicular Neoplasms (Bethesda IV Nodules). Ann Surg. 2020; 272(4):621-627. DOI: 10.1097/SLA.0000000000004130. View

Chen B, Shi Y, Xu Y, Zhang J . The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2020; 94(5):731-742. DOI: 10.1111/cen.14316. View

Cibas E, Ali S . The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017; 27(11):1341-1346. DOI: 10.1089/thy.2017.0500. View

Cipriani N . Prognostic Parameters in Differentiated Thyroid Carcinomas. Surg Pathol Clin. 2019; 12(4):883-900. DOI: 10.1016/j.path.2019.07.001. View

Dobrinja C, Troian M, Cipolat Mis T, Rebez G, Bernardi S, Fabris B . Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center. Int J Surg. 2017; 41 Suppl 1:S40-S47. DOI: 10.1016/j.ijsu.2017.01.113. View

Du E, Wenig B, Su H, Rowe M, Haser G, Asa S . Inter-Observer Variation in the Pathologic Identification of Extranodal Extension in Nodal Metastasis from Papillary Thyroid Carcinoma. Thyroid. 2016; 26(6):816-9. DOI: 10.1089/thy.2015.0551. View

10.

Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli J . Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006; 91(8):2892-9. DOI: 10.1210/jc.2005-2838. View

11.

Durante C, Hegedus L, Czarniecka A, Paschke R, Russ G, Schmitt F . 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. Eur Thyroid J. 2023; 12(5). PMC: 10448590. DOI: 10.1530/ETJ-23-0067. View

12.

Feng J, Qu Z, Qin A, Pan H, Ye J, Jiang Y . Significance of multifocality in papillary thyroid carcinoma. Eur J Surg Oncol. 2020; 46(10 Pt A):1820-1828. DOI: 10.1016/j.ejso.2020.06.015. View

13.

Filetti S, Durante C, Hartl D, Leboulleux S, Locati L, Newbold K . Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(12):1856-1883. DOI: 10.1093/annonc/mdz400. View

14.

Furlan J, Bedard Y, Rosen I . Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas. J Am Coll Surg. 2004; 198(3):341-8. DOI: 10.1016/j.jamcollsurg.2003.11.012. View

15.

Giordano D, Frasoldati A, Gabrielli E, Pernice C, Zini M, Castellucci A . Long-term outcomes of central neck dissection for cN0 papillary thyroid carcinoma. Am J Otolaryngol. 2017; 38(5):576-581. DOI: 10.1016/j.amjoto.2017.06.004. View

16.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

17.

Iacobone M, Jansson S, Barczynski M, Goretzki P . Multifocal papillary thyroid carcinoma--a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2013; 399(2):141-54. DOI: 10.1007/s00423-013-1145-7. View

18.

Jin B, Kim M, Ji Y, Song C, Park J, Tae K . Characteristics and significance of minimal and maximal extrathyroidal extension in papillary thyroid carcinoma. Oral Oncol. 2015; 51(8):759-63. DOI: 10.1016/j.oraloncology.2015.05.010. View

19.

Joseph K, Edirimanne S, Eslick G . Multifocality as a prognostic factor in thyroid cancer: A meta-analysis. Int J Surg. 2018; 50:121-125. DOI: 10.1016/j.ijsu.2017.12.035. View

20.

Kim S, Lee K, Myong J, Park J, Jeon Y, Min H . BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2011; 36(2):310-7. DOI: 10.1007/s00268-011-1383-1. View